GH001 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant Depression
Conditions
Treatment-resistant Depression
Trial Timeline
May 24, 2023 → Mar 11, 2025
NCT ID
NCT05800860About GH001 + Placebo
GH001 + Placebo is a phase 2 stage product being developed by GH Research for Treatment-resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT05800860. Target conditions include Treatment-resistant Depression.
What happened to similar drugs?
0 of 2 similar drugs in Treatment-resistant Depression were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05800860 | Phase 2 | Completed |
Competing Products
6 competing products in Treatment-resistant Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 35 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 35 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 29 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 39 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 25 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 37 |